{"id":1689,"date":"2020-07-09T12:13:00","date_gmt":"2020-07-09T11:13:00","guid":{"rendered":"https:\/\/tris.sambrownprojects.com\/tris-pharma-and-kye-pharmaceuticals-announce-exclusive-license-agreement-to-commercialize-tris-adhd-products-in-canada\/"},"modified":"2024-06-03T11:11:03","modified_gmt":"2024-06-03T10:11:03","slug":"tris-pharma-and-kye-pharmaceuticals-announce-exclusive-license-agreement-to-commercialize-tris-adhd-products-in-canada","status":"publish","type":"post","link":"https:\/\/www.trispharma.com\/tris-pharma-and-kye-pharmaceuticals-announce-exclusive-license-agreement-to-commercialize-tris-adhd-products-in-canada\/","title":{"rendered":"Tris Pharma and KYE Pharmaceuticals Announce Exclusive License Agreement to Commercialize Tris ADHD Products in Canada"},"content":{"rendered":"\r\n<p>MONMOUTH JUNCTION, NJ and MISSISSAUGA, ONTARIO, CANADA, July 9, 2020\/ PRNewswire\/ &#8211; Tris Pharma, Inc. (&#8220;Tris&#8221;), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, and KYE Pharmaceuticals Inc. (\u201cKYE\u201d), a private company headquartered in Mississauga, Ontario and focused on the Canadian market, announced today that they have entered into an agreement whereby KYE received exclusive rights to &nbsp;commercialize Tris\u2019 FDA-approved ADHD product portfolio in Canada. &nbsp;Under the terms of this agreement, KYE will also handle all ongoing Canadian regulatory activities for the products.<\/p>\r\n\r\n\r\n\r\n<p>\u201cPartnering with Tris to bring this unique ADHD product portfolio to Canada is a defining opportunity,\u201d said Doug Reynolds, President of KYE. \u201cTris\u2019 products have the potential to address a void that has long existed in the treatment of ADHD.&nbsp; In addition to the unique clinical profile of each of the Tris products, many young patients ro<a>utinely struggle with swallowing pills a<\/a>nd\/or finding the optimal dose. Tris\u2019 long acting once-daily liquids of both methylphenidate and amphetamine position KYE to change the standard of care by alleviating the challenges associated with young children being forced to swallow large tablets, providing dosing consistency not possible when caregivers are forced to open and sprinkle capsules, and allowing for improved dosing customization.\u201d<\/p>\r\n\r\n\r\n\r\n<p>\u201cThough we\u2019ve often been approached to make our ADHD portfolio available outside the United States, this agreement is the first time we will seek to do so and therefore represents an important milestone for Tris as a company,\u201d said Ketan Mehta, Tris\u2019 Founder and CEO. \u201cGiven the KYE leadership team\u2019s proven track record of successful commercialization in Canada, we believe they are an excellent partner to drive commercial value and get our products into the hands of Canadian patients.\u201d<\/p>\r\n\r\n\r\n\r\n<p><strong>About Tris Pharma<\/strong><\/p>\r\n\r\n\r\n\r\n<p>Tris Pharma is a New Jersey-based specialty pharmaceutical company focused on the development and commercialization of innovative medicines that address unmet patient needs. Tris has used its innovative LiquiXR technology platform to develop its portfolio of differentiated solid and liquid ADHD products (described at <a href=\"https:\/\/www.trisadhd.com\/\">www.TrisADHD.com<\/a>), which it markets in the United States using its pediatric and CNS-focused sales force. The company has leveraged its technology platform to establish a robust product pipeline as well as numerous mutually value-adding development partnerships. For more information, please visit <a href=\"https:\/\/www.trispharma.com\">www.trispharma.com<\/a>.<\/p>\r\n\r\n\r\n\r\n<p><strong>About KYE Pharmaceuticals<\/strong><\/p>\r\n\r\n\r\n\r\n<p>KYE Pharmaceuticals is a private company headquartered in Canada focused on bringing medications to the Canadian market which fulfill clinically significant and unmet needs. KYE has licensed many innovative products and was founded on an entrepreneurial spirit that optimizes our team\u2019s strengths and brings unique value to our partners, Canadian healthcare professionals, and most importantly, our patients. For more information please visit <a href=\"http:\/\/www.kyepharma.com\">www.kyepharma.com<\/a>. &nbsp;&nbsp;<\/p>\r\n","protected":false},"excerpt":{"rendered":"<p>MONMOUTH JUNCTION, NJ and MISSISSAUGA, ONTARIO, CANADA, July 9, 2020\/ PRNewswire\/ &#8211; Tris Pharma, Inc. (&#8220;Tris&#8221;), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, and KYE Pharmaceuticals Inc. (\u201cKYE\u201d), a private company headquartered in Mississauga, Ontario and focused on the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":"","_wp_rev_ctl_limit":""},"categories":[28],"tags":[],"class_list":["post-1689","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"featured_image_src":{"landsacpe":false,"list":false,"medium":false,"full":false},"yoast_head":"\n<title>Tris Pharma and KYE Pharmaceuticals Announce Exclusive License Agreement to Commercialize Tris ADHD Products in Canada - Tris Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.trispharma.com\/tris-pharma-and-kye-pharmaceuticals-announce-exclusive-license-agreement-to-commercialize-tris-adhd-products-in-canada\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tris Pharma and KYE Pharmaceuticals Announce Exclusive License Agreement to Commercialize Tris ADHD Products in Canada - Tris Pharma\" \/>\n<meta property=\"og:description\" content=\"MONMOUTH JUNCTION, NJ and MISSISSAUGA, ONTARIO, CANADA, July 9, 2020\/ PRNewswire\/ &#8211; Tris Pharma, Inc. (&#8220;Tris&#8221;), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, and KYE Pharmaceuticals Inc. (\u201cKYE\u201d), a private company headquartered in Mississauga, Ontario and focused on the [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.trispharma.com\/tris-pharma-and-kye-pharmaceuticals-announce-exclusive-license-agreement-to-commercialize-tris-adhd-products-in-canada\/\" \/>\n<meta property=\"og:site_name\" content=\"Tris Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-09T11:13:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-03T10:11:03+00:00\" \/>\n<meta name=\"author\" content=\"rajeshlohakare@sambrown.com\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"rajeshlohakare@sambrown.com\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.trispharma.com\/tris-pharma-and-kye-pharmaceuticals-announce-exclusive-license-agreement-to-commercialize-tris-adhd-products-in-canada\/\",\"url\":\"https:\/\/www.trispharma.com\/tris-pharma-and-kye-pharmaceuticals-announce-exclusive-license-agreement-to-commercialize-tris-adhd-products-in-canada\/\",\"name\":\"Tris Pharma and KYE Pharmaceuticals Announce Exclusive License Agreement to Commercialize Tris ADHD Products in Canada - Tris Pharma\",\"isPartOf\":{\"@id\":\"https:\/\/www.trispharma.com\/#website\"},\"datePublished\":\"2020-07-09T11:13:00+00:00\",\"dateModified\":\"2024-06-03T10:11:03+00:00\",\"author\":{\"@id\":\"https:\/\/www.trispharma.com\/#\/schema\/person\/a23b5071b857390e7221beef1ae32be2\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.trispharma.com\/tris-pharma-and-kye-pharmaceuticals-announce-exclusive-license-agreement-to-commercialize-tris-adhd-products-in-canada\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.trispharma.com\/tris-pharma-and-kye-pharmaceuticals-announce-exclusive-license-agreement-to-commercialize-tris-adhd-products-in-canada\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.trispharma.com\/tris-pharma-and-kye-pharmaceuticals-announce-exclusive-license-agreement-to-commercialize-tris-adhd-products-in-canada\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.trispharma.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tris Pharma and KYE Pharmaceuticals Announce Exclusive License Agreement to Commercialize Tris ADHD Products in Canada\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.trispharma.com\/#website\",\"url\":\"https:\/\/www.trispharma.com\/\",\"name\":\"Tris Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.trispharma.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.trispharma.com\/#\/schema\/person\/a23b5071b857390e7221beef1ae32be2\",\"name\":\"rajeshlohakare@sambrown.com\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.trispharma.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/83cec6f9d7f6fd867342a65ffe372ccb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/83cec6f9d7f6fd867342a65ffe372ccb?s=96&d=mm&r=g\",\"caption\":\"rajeshlohakare@sambrown.com\"},\"sameAs\":[\"http:\/\/tris.sambrownprojects.com\"],\"url\":\"https:\/\/www.trispharma.com\/author\/rajeshlohakaresambrown-com\/\"}]}<\/script>\n","yoast_head_json":{"title":"Tris Pharma and KYE Pharmaceuticals Announce Exclusive License Agreement to Commercialize Tris ADHD Products in Canada - Tris Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.trispharma.com\/tris-pharma-and-kye-pharmaceuticals-announce-exclusive-license-agreement-to-commercialize-tris-adhd-products-in-canada\/","og_locale":"en_GB","og_type":"article","og_title":"Tris Pharma and KYE Pharmaceuticals Announce Exclusive License Agreement to Commercialize Tris ADHD Products in Canada - Tris Pharma","og_description":"MONMOUTH JUNCTION, NJ and MISSISSAUGA, ONTARIO, CANADA, July 9, 2020\/ PRNewswire\/ &#8211; Tris Pharma, Inc. (&#8220;Tris&#8221;), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, and KYE Pharmaceuticals Inc. (\u201cKYE\u201d), a private company headquartered in Mississauga, Ontario and focused on the [&hellip;]","og_url":"https:\/\/www.trispharma.com\/tris-pharma-and-kye-pharmaceuticals-announce-exclusive-license-agreement-to-commercialize-tris-adhd-products-in-canada\/","og_site_name":"Tris Pharma","article_published_time":"2020-07-09T11:13:00+00:00","article_modified_time":"2024-06-03T10:11:03+00:00","author":"rajeshlohakare@sambrown.com","twitter_card":"summary_large_image","twitter_misc":{"Written by":"rajeshlohakare@sambrown.com","Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.trispharma.com\/tris-pharma-and-kye-pharmaceuticals-announce-exclusive-license-agreement-to-commercialize-tris-adhd-products-in-canada\/","url":"https:\/\/www.trispharma.com\/tris-pharma-and-kye-pharmaceuticals-announce-exclusive-license-agreement-to-commercialize-tris-adhd-products-in-canada\/","name":"Tris Pharma and KYE Pharmaceuticals Announce Exclusive License Agreement to Commercialize Tris ADHD Products in Canada - Tris Pharma","isPartOf":{"@id":"https:\/\/www.trispharma.com\/#website"},"datePublished":"2020-07-09T11:13:00+00:00","dateModified":"2024-06-03T10:11:03+00:00","author":{"@id":"https:\/\/www.trispharma.com\/#\/schema\/person\/a23b5071b857390e7221beef1ae32be2"},"breadcrumb":{"@id":"https:\/\/www.trispharma.com\/tris-pharma-and-kye-pharmaceuticals-announce-exclusive-license-agreement-to-commercialize-tris-adhd-products-in-canada\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.trispharma.com\/tris-pharma-and-kye-pharmaceuticals-announce-exclusive-license-agreement-to-commercialize-tris-adhd-products-in-canada\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.trispharma.com\/tris-pharma-and-kye-pharmaceuticals-announce-exclusive-license-agreement-to-commercialize-tris-adhd-products-in-canada\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.trispharma.com\/"},{"@type":"ListItem","position":2,"name":"Tris Pharma and KYE Pharmaceuticals Announce Exclusive License Agreement to Commercialize Tris ADHD Products in Canada"}]},{"@type":"WebSite","@id":"https:\/\/www.trispharma.com\/#website","url":"https:\/\/www.trispharma.com\/","name":"Tris Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.trispharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/www.trispharma.com\/#\/schema\/person\/a23b5071b857390e7221beef1ae32be2","name":"rajeshlohakare@sambrown.com","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.trispharma.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/83cec6f9d7f6fd867342a65ffe372ccb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/83cec6f9d7f6fd867342a65ffe372ccb?s=96&d=mm&r=g","caption":"rajeshlohakare@sambrown.com"},"sameAs":["http:\/\/tris.sambrownprojects.com"],"url":"https:\/\/www.trispharma.com\/author\/rajeshlohakaresambrown-com\/"}]}},"_links":{"self":[{"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/posts\/1689"}],"collection":[{"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/comments?post=1689"}],"version-history":[{"count":1,"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/posts\/1689\/revisions"}],"predecessor-version":[{"id":2932,"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/posts\/1689\/revisions\/2932"}],"wp:attachment":[{"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/media?parent=1689"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/categories?post=1689"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/tags?post=1689"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}